2'-deoxy-2'-fluoroguanosine: has activity in human respiratory epithelial cells against both influenza A & B viruses [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 135415565 |
CHEMBL ID | 308759 |
SCHEMBL ID | 236684 |
SCHEMBL ID | 15532083 |
MeSH ID | M0222522 |
Synonym |
---|
CHEMBL308759 , |
2'-deoxy-2'-fluoroguanosine |
guanosine, 2'-deoxy-2'-fluoro- |
2-amino-9-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-purin-6-one |
2-amino-9-((2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one |
bdbm50144930 |
2-amino-9-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one |
78842-13-4 |
2-amino-9-((2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1h-purin-6(9h)-one |
AKOS016003829 |
2'-dfgs |
2'-fluoro-2'-deoxyguanosine |
HG1070 |
SCHEMBL236684 |
2-amino-9-((2s,3s,4s,5s)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1h-purin-6(9h)-one |
9-(2-deoxy-2-fluoro-beta-d-ribofuranosyl)guanine |
UXUZARPLRQRNNX-DXTOWSMRSA-N |
J-700052 |
DTXSID40229334 |
2'-fluoro -2'-deoxyguanosine |
SCHEMBL15532083 |
2-amino-9-((2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6h-purin-6-one |
2-amino-9-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-purin-6-one |
AC-9551 |
deoxyfluoroguanosine |
AS-49377 |
2'-fluoro-2'-deoxy-d-guanosine |
2-fluoro -2-deoxyguanosine |
2-amino-9-((2s,3s,4s,5s)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1h-purin-6(9h)-one;2'-fluoro-2'-deoxyguanosine |
A848809 |
CS-W012234 |
HY-W011518 |
2 inverted exclamation marka-deoxy-2 inverted exclamation marka-fluoroguanosine |
2-fluoro-2-deoxyguanosine |
AKOS040756306 |
2??-deoxy-2??-fluoroguanosine |
BP-58854 |
Excerpt | Reference |
---|---|
" In ferrets infected with influenza B virus, single-dose treatment (40 mg/kg given intraperitoneally) produced a similar but reduced response in comparison with that in ferrets infected with influenza A virus, indicating that dosing was not optimal for this virus." | ( Efficacy of 2'-deoxy-2'-fluororibosides against influenza A and B viruses in ferrets. Jakeman, KJ; Leone, A; Russell, S; Sweet, C; Tisdale, M, 1994) |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | EC50 (µMol) | 50.0000 | 0.0026 | 0.5334 | 1.2020 | AID86857 |
RNA-directed RNA polymerase | EC50 (µMol) | 50.0000 | 0.0018 | 0.2348 | 2.8000 | AID86857 | |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1204707 | Antiviral activity against RSV A2 infected in human Hep2 cells assessed as protection against virus-induced cytopathic effect after 4 days by Cell-Titer Glo assay | 2015 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12 | Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases. |
AID1204710 | Inhibition of human mitochondrial DNA polymerase gamma large subunit/DNA polymerase gamma accessory subunit using 32P-D19/D36 as DNA primer/template assessed as single nucleotide incorporation rate at 100 uM after 5 to 90 mins by PAGE analysis relative to | 2015 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12 | Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases. |
AID86857 | Inhibition HCV RNA replication | 2004 | Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9 | Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. |
AID1204711 | Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by Cell-Titer Glo assay | 2015 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12 | Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases. |
AID1204708 | Inhibition of RSV A2 RNA-dependent RNA polymerase expressed in human Hep2 cells using ATP, GTP, UTP, CTP and 1.5 uCi [alpha-32P] NTP as substrate assessed as reduction of total radiolabled transcript after 90 mins by agarose gel electrophoresis | 2015 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12 | Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases. |
AID1204709 | Inhibition of human mitochondrial RNA polymerase using 5'-32P-R12/D18 as RNA/DNA template assessed as single nucleotide incorporation rate at 500 uM after 0.17 to 30 mins by PAGE analysis | 2015 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12 | Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases. |
AID86859 | Compound was evaluated for inhibition HCV NS5B-mediated RNA synthesis; Substrate | 2004 | Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9 | Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (62.50) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 2 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |